Nestle Pays $2 Bln to Secure Aimmune ' s Allergy Treatment Nestle Pays $2 Bln to Secure Aimmune ' s Allergy Treatment

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Business of Medicine News Source Type: news